ALEMBICLTDNSEAlembic Limited· PharmaceuticalsHighPositive
Announced Tue, 13 May · 17:40 IST

Alembic Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2025, recommended Final Dividend of Rs. 2.40 per equity share.

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionEmphasis Of MatterResults View source PDF

ALEMBICLTD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Alembic Limited's Board approved audited consolidated and standalone results for Q4 and FY ended March 31, 2025. Consolidated revenue from operations grew about 41% YoY to Rs. 22,189 lakhs (from Rs. 15,749 lakhs), while consolidated net profit after tax rose roughly 56% to Rs. 14,457 lakhs (from Rs. 9,287 lakhs). Including share of associate Alembic Pharmaceuticals, total comprehensive income stood at Rs. 27,636 lakhs for FY25. Standalone performance was similarly strong, with revenue up around 41% to Rs. 21,436 lakhs and PAT up about 53% to Rs. 14,195 lakhs, lifting standalone EPS to Rs. 5.53 from Rs. 3.62. The Board recommended a final dividend of Rs. 2.40 per share (120% on face value of Rs. 2), unchanged from the previous year, subject to shareholder approval. The auditor (CNK & Associates LLP) issued an unmodified opinion but flagged an Emphasis of Matter on a disputed electricity duty matter where Rs. 2,052 lakhs has been provided and Rs. 3,500 lakhs deposited with the Supreme Court. Operating cash flow improved sharply to Rs. 8,637 lakhs (consolidated) from Rs. 2,269 lakhs.

Likely market impact

Strong topline and bottomline growth, healthy dividend maintained, and cleaner operating cash flows are positive for shareholders, though the ongoing electricity duty dispute remains a watchable overhang.